PTEN sirna

PTEN siRNA (Human)

Cat. Num. AAA8219286

• Gene Names: PTEN; BZS; DEC; CWS1; GLM2; MHAM; TEP1; MMAC1; PTEN1; 10q23del
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: PTEN; PTEN siRNA (Human); MMAC1; TEP1; Phosphatidylinositol 3.4.5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; Mutated in multiple advanced cancers 1; Phosphatase and tensin homolog; PTEN sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: PTEN siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 403

• Applicable Applications for PTEN sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human PTEN gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for PTEN sirna

siRNA to inhibit PTEN expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 73765544
• NCBI GeneID: 5728
• NCBI Accession #: NP_000305.3
• NCBI GenBank Nucleotide #: NM_000314.6
• UniProt Accession #: P60484; O00633; O02679; Q6ICT7; B2R904; F2YHV0
• Molecular Weight: 19,796 Da
• NCBI Official Full Name: phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN isoform PTEN
• NCBI Official Synonym Full Names: phosphatase and tensin homolog
• NCBI Official Symbol: PTEN
• NCBI Official Synonym Symbols: BZS; DEC; CWS1; GLM2; MHAM; TEP1; MMAC1; PTEN1; 10q23del
• NCBI Protein Information: phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
• UniProt Protein Name: Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
• Protein Family: Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase
• UniProt Gene Name: PTEN
• UniProt Synonym Gene Names: MMAC1; TEP1
• UniProt Entry Name: PTEN_HUMAN

NCBI Description

This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate energy metabolism in the mitochondria. A pseudogene of this gene is found on chromosome 9. Alternative splicing and the use of multiple translation start codons results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2015]

Uniprot Description

PTEN: a phosphoinositide 3-phosphatase (PIP3) and a tumor suppressor implicated in a wide variety of human cancers. Dephosphorylates inositol phospholipids generated by the activation of the phosphoinositide 3 kinase (PI3K). A major negative regulator of the PI3K/Akt signaling pathway. Possesses a C-terminal regulatory domain that contains three phosphorylation sites which may regulate its stability.

Protein type: EC 3.1.3.48; Phosphatase, lipid; EC 3.1.3.67; Motility/polarity/chemotaxis; Carbohydrate Metabolism - inositol phosphate; Tumor suppressor; EC 3.1.3.16; Nuclear receptor co-regulator

Chromosomal Location of Human Ortholog: 10q23.3

Cellular Component: nucleoplasm; postsynaptic membrane; PML body; internal side of plasma membrane; neuron projection; cell projection; mitochondrion; cytoplasm; plasma membrane; extracellular region; dendritic spine; cytosol; nucleus

Molecular Function: phosphatidylinositol-3-phosphatase activity; phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity; platelet-derived growth factor receptor binding; magnesium ion binding; protein tyrosine phosphatase activity; protein serine/threonine phosphatase activity; protein kinase binding; PDZ domain binding; protein binding; enzyme binding; phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; protein tyrosine/serine/threonine phosphatase activity; phosphoprotein phosphatase activity; lipid binding

Biological Process: central nervous system development; male mating behavior; prepulse inhibition; nerve growth factor receptor signaling pathway; response to arsenic; regulation of cellular component size; heart development; anaphase-promoting complex activation during mitotic cell cycle; Wnt receptor signaling pathway through beta-catenin; T cell receptor signaling pathway; regulation of B cell apoptosis; myelin maintenance in the central nervous system; response to glucose stimulus; negative regulation of axonogenesis; response to drug; rhythmic synaptic transmission; dentate gyrus development; fibroblast growth factor receptor signaling pathway; negative regulation of myelination; social behavior; forebrain morphogenesis; negative regulation of organ growth; response to ethanol; response to zinc ion; inositol phosphate dephosphorylation; phosphatidylinositol biosynthetic process; endothelial cell migration; positive regulation of transcription factor activity; multicellular organismal response to stress; negative regulation of apoptosis; negative regulation of phagocytosis; synapse maturation; inositol phosphate metabolic process; apoptosis; regulation of protein stability; negative regulation of cell size; locomotory behavior; platelet-derived growth factor receptor signaling pathway; regulation of myeloid cell apoptosis; protein amino acid dephosphorylation; response to estradiol stimulus; locomotor rhythm; negative regulation of cell proliferation; synaptogenesis; learning and/or memory; negative regulation of protein amino acid phosphorylation; phospholipid metabolic process; positive regulation of cell proliferation; protein kinase B signaling cascade; brain morphogenesis; nerve-nerve synaptic transmission; angiogenesis; negative regulation of cell migration; response to nutrient; aging; negative regulation of epithelial cell proliferation; epidermal growth factor receptor signaling pathway; cardiac muscle development; cell migration; phosphoinositide-mediated signaling; negative regulation of protein kinase B signaling cascade; protein stabilization; central nervous system neuron axonogenesis; maternal behavior; negative regulation of focal adhesion formation; response to ATP; memory; cell proliferation; G1/S-specific negative regulation of cyclin-dependent protein kinase activity; innate immune response; phosphoinositide dephosphorylation; regulation of cyclin-dependent protein kinase activity; negative regulation of phosphoinositide 3-kinase cascade

Disease: Meningioma, Familial, Susceptibility To; Thyroid Carcinoma, Follicular; Melanoma, Cutaneous Malignant, Susceptibility To, 1; Bannayan-riley-ruvalcaba Syndrome; Cowden Syndrome 1; Squamous Cell Carcinoma, Head And Neck; Glioma Susceptibility 2; Prostate Cancer; Vacterl Association With Hydrocephalus; Endometrial Cancer; Macrocephaly/autism Syndrome